Antiplatelet agents and proton pump inhibitors - personalizing treatment

Pharmacogenomics and Personalized Medicine

Volumn 3, Issue 1, 2010, Pages 101-109

  Lin, Eugene ^a   Padmanabhan, Rajiv ^a   Moonis, Majaz ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Antiplatelet medications; Cardiovascular events; Clopidogrel; Ischemic stroke; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PRASUGREL; PROTON PUMP INHIBITOR; RABEPRAZOLE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM ULCER; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; HUMAN; LOW DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PHARMACOGENOMICS; REVIEW; TRANSIENT ISCHEMIC ATTACK;

EID: 77955569464     PISSN: None     EISSN: 11787066     Source Type: Book Series    
DOI: None     Document Type: Review

References (44)

1. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke. 2008;39(5):1647-1652.
2. FDA. Information for Healthcare Professionals: Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). 2009. Accessed Nov 18, 2009.
3. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome. Circulation. 2009;120(23):2322-2329.
4. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329):71-86.
5. ESPRIT Study Group; Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367(9523):1665-1673.
6. Diener HC, Sacco RL, Yusuf S, et al. Effects of aspirin plus extendedrelease dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7(10):875-884.
7. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebocontrolled trial. Lancet. 2005;366(9497):1607-1621.
8. Yusuf S, Zhao F, Mehta SR, et al. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST- Segment Elevation. N Engl J Med. 2001;345(7):494-502.
9. Becker RC, Scheiman J, Dauerman HL, et al. Management of Platelet- Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures. J Am Coll Cardiol. 2009;54(24):2261-2276.
10. Kushner FG, Hand M, Smith SC Jr. et al. 2009 Focused Updates: ACC/ AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Catheter Cardiovasc Interv. 2009;74(7):E25-E68.
11. Patel D, Moonis M. Clinical implications of aspirin resistance. Expert Rev Cardiovasc Ther. 2007;5(5):969-975.
12. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin ' resistance' and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336(7637):195-198.
13. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321(7270):1183-1187.
14. Arora G, Singh G, Triadafilopoulos G. Proton Pump Inhibitors for Gastroduodenal Damage Related to Nonsteroidal Anti-inflammatory Drugs or Aspirin: Twelve Important Questions for Clinical Practice. Clin Gastroenterol Hepatol. 2009;7(7):725-735.
15. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the Prevention of Recurrences of Ulcer Complications from Long-Term Low-Dose Aspirin Use. N Engl J Med. 2002;346(26):2033-2038.
16. Iñarrea P, Esteva F, Cornudella R, Lanas A. Omeprazole Does Not Interfere with the Antiplatelet Effect of Low-Dose Aspirin in Man. Scand J Gastroenterol. 2000;35:242-246.
17. Derendorf H, VanderMaelen CP, Brickl RS, MacGregor TR, Eisert W. Dipyridamole Bioavailability in Subjects With Reduced Gastric Acidity. J Clin Pharmacol. 2005;45(7):845-850.
18. Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost. 1994;72(2):313-317.
19. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and Biological Activity of the Active Metabolite of Clopidogrel. Thromb Haemost. 2000;84(5):891-896.
20. Weber AA, Braun M, Hohlfeld T, Schwippert B, Tschöpe D, Schrör K. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol. 2001;52(3): 333-336.
21. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116(3):496-526.
22. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 Polymorphisms and Response to Clopidogrel. N Engl J Med. 2009;360(4):354-362.
23. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309-317.
24. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy. JAMA. 2009;302(8):849-857.
25. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism. Clin Pharmacokinet 2002;41(12):913-958.
26. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52(18): 1502-1517.
27. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Effect of Antisecretory Drugs and Nitrates on the Risk of Ulcer Bleeding Associated With Nonsteroidal Anti-Inflammatory Drugs, Antiplatelet Agents, and Anticoagulants. Am J Gastroenterol. 2007;102(3):507-515.
28. Kwong Ming F, Tiing Leong A, Lean Choo B, Edmund Jon Deon L. Proton Pump Inhibitors: Do Differences in Pharmacokinetics Translate into Differences in Clinical Outcomes? Clin Pharmacokinet. 2008; 47:1-6.
29. Norgard NB, Mathews KD, Wall GC. Drug-Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors. Ann Pharmacother. 2009;43(7):1266-1274.
30. Gilard M, Arnaud B, Gal GL, Abgrall JF, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006;4(11):2508-2509.
31. Gilard M, Arnaud B, Cornily JC, et al. Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin: The Randomized, Double-Blind OCLA (Omeprazole CLopidogrel Aspirin) Study. J Am Coll Cardiol. 2008;51(3):256-260.
32. Small DS, Farid NA, Payne CD, et al. Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel. J Clin Pharmacol. April 1, 2008 2008;48(4): 475-484.
33. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009 Jan;157(1):148.e1-e5. Epub 2008 Nov 6.
34. Sibbing DM, Tanja, Stegherr, Julia et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;101(4):714-719.
35. Cuissett T, Frere C, Quilici J, et al. Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose: The PACA (Proton Pump Inhibitors And Clopidogrel Association) Prospective Randomized Study. J Am Coll Cardiol. 2009;54(13):1149-1153.
36. Ray WA, Murray KT, Griffin MR, et al. Outcomes With Concurrent Use of Clopidogrel and Proton-Pump Inhibitors. Ann Intern Med. 2010; 152(6):337-345.
37. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989-997.
38. Ramirez JF. Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcomes after PCI: The NHLBI Dynamic Registry. Presented at: American College of Cardiology Session/i2 Summit, March 29, 2009; Orlando, FL.; http://www.tctmd.com/show.aspx?id=77266
39. Bhatt DL, Cryer MM, Byron MD, Contant CF, et al. COGENT: A prospective, randomized, placebo-controlled trial of omeprazole in patients receiving aspirin and clopidogrel. Transvascular Cardiovascular Therapeutics Annual Meeting. Sept 2009.
40. Dunn SP, Macaulay TE, Brennan DM, et al. Abstract 3999: Baseline Proton Pump Inhibitor Use is Associated with Increased Cardiovascular Events With and Without the Use of Clopidogrel in the CREDO Trial. Circulation. 2008;118(18_MeetingAbstracts):S_1458.
41. Pezalla E, Day D, Pulliadath I. Initial Assessment of Clinical Impact of a Drug Interaction Between Clopidogrel and Proton Pump Inhibitors. J Am Coll Cardiol. 2008;52(12):1038-1039.
42. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009 Mar 31. 2009;180(7):713-718.
43. Ho PM, Maddox TM, Wang L, et al. Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome. JAMA. 2009;301(9): 937-944.
44. Stanek EJ, Aubert RE, Flockhart DA, et al. A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: The Clopidogrel Medco Outcomes Study. 2009. http:// www.theheart.org/article/967075.do.